This article argues that correctional institutions violate the Eighth Amendment when they refuse to establish MAT programs and prevent doctors from exercising medical judgment to properly treat incarcerated people with OUD.
J.Bronsonet al., Bureau of Justice Statistics, Drug Use, Dependence, and Abuse Among State Prisoners and Jail Inmates, 2007-2009, NCJ 250546 (June2017).
4.
See Section III. infra.
5.
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (Arlington, VA: American Psychiatric Association Publishing, 2013).
Center for Substance Abuse Treatment, Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs, Treatment Improvement Protocol Series 43 (Revised 2012).
8.
T.W.Park and P.D.Friedmann, “Medication for Addiction Treatment: An Opportunity for Prescribing Clinicians to Facilitates Remission from Alcohol and Opioid Use Disorders,”Rhode Island Medical Journal97, no. 10 (2014): 20-24, at 22-23.
9.
Williams, supra note 6; see alsoP.D.Friedmannet al., “Medication-Assisted Treatment in Criminal Justice Agencies Affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, Barriers & Intentions,”Substance Abuse33 (2012): 9-18, at 12; A. Nunn et al., “Metha-done and Buprenorphine Prescribing and Referral Practices in US Prison Systems: Results from a Nationwide Survey,” Drug and Alcohol Dependence 105 (2009): 83-88, at 84-85; B. Schwartzapfel, “A Better Way to Treat Addiction in Jail,” The Marshall Project, March 1, 2017, available at <https://www.themarshallproject.org/2017/03/01/a-better-way-to-treat-addiction-in-jail> (last visited April 6, 2018).
10.
R.K.Chandleret al., “Treating Drug Abuse and Addiction in the Criminal Justice System: Improving Public Health and Safety,”JAMA301 (2009): 183-190, at 185.
11.
T.Greeneet al., “Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System,”JAMA Psychiatry (February14, 2018): E1-E3, at E1, available at <https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2671411> (last visited April 6, 2018).
12.
See Section IV.
13.
For an excellent overview of the topic, seeD.Lebowitz, “‘Proper Subjects for Medical Treatment?’ Addiction, Prison-Based Drug Treatment, and the Eighth Amendment,”DePaul Journal of Healthcare Law14, no. 2 (2012): 271-308.
14.
.S. Constitution, amendment VIII.
15.
Estelle v. Gamble, 429 U.S. 97, 103 (1976).
16.
Id., at 99.
17.
Id., at 100.
18.
Id.
19.
Id., at 100-01.
20.
Id., at 104.
21.
Id.
22.
Id., at 105.
23.
Id., at 106
24.
Madrid v. Gomez, 889 F. Supp. 1146, 1210 (N.D. Cal. 1995).
25.
Id., at 1215.
26.
Coleman v. Wilson, 912 F. Supp. 1282, 1316, 1319 (E.D. Cal. 1995).
Braggs v. Dunn, 257 F. Supp. 3d 1171, 1267 (M.D. Ala. 2017).
32.
Dunn v. Dunn, 219 F. Supp. 3d 1100, 1123 (M.D. Ala. 2016).
33.
See e.g., Postawko v. Mo. Dep’t Corr., 2017 U.S. Dist. LEXIS 117238, at *51 (W.D. Mo.); Lipert v. Baldwin, 2017 U.S. Dist. LEXIS 64687, at *28 (N.D. Ill.).
34.
Hoffer v. Jones, 2017 U.S. Dist. LEXIS 194544, at *6 (N.D. Fla.).
Jones v. Bradshaw, 2017 U.S. Dist. LEXIS 46829, at *26-27 (S.D. Fla.).
43.
Bowring v. Godwin, 551 F.2d 44, 48 (4th Cir. 1977).
44.
Tarver v. McLaughlin, 2017 U.S. Dist. LEXIS 129737, at *12 (M.D. Ga.).
45.
Corley v. Wexford Health Sources, Inc., 2016 U.S. Dist. LEXIS 122306, at *31 (S.D. Ill.).
46.
Knop v. Johnson, 667 F.Supp. 512, 528 (W.D. Mich. 1987).
47.
Prosser v. Nagaldinne, 927 F. Supp. 2d 708, 728 (E.D. Mo. 2013).
48.
King v. Kramer, 680 F.3d 1013, 1019 (7th Cir. 2012).
49.
McGiboney v. CCA Western Props., 2016 U.S. Dist. LEXIS 27491, at *23-24 (D. Idaho).
50.
Hoptowit v. Ray, 682 F.2d 1237, 1253 (9th Cir. 1982).
51.
Waldrop v. Evans, 871 F.2d 1030, 1035 (11th Cir. 1989).
52.
United States v. DeCologero, 821 F.2d 39, 43 (1st Cir. 1987).
53.
Nauroth v. Southern Health Partners, Inc., 2009 U.S. Dist. LEXIS *86467, at *33 (S.D. Ohio).
54.
Butler v. City of Pontiac, 2006 U.S. Dist. LEXIS 55845, at *18 (E.D. Mich.).
55.
Harris v. Thigpen, 941 F.2d 1495, 1509 (11th Cir. 1991).
56.
Dunn v. Dunn, 219 F. Supp. 3d at 1130.
57.
Estelle, 429 U.S. at 104.
58.
Helling v. McKinney, 509 U.S. 25, 27-28 (1993).
59.
McKinney v. Anderson, 924 F.2d 1500, 1505-09 (9th Cir. 1991), vacated, 502 U.S. 903 (1991).
60.
Helling, 509 U.S. at 30, 33.
61.
Id., at 33.
62.
Id., at 36.
63.
See Wakefield v. Thomas, 777 F.3d 1160 (9th Cir. 1999); Lugo v. Senkowski, 114 F. Supp. 2d 111 (N.D.N.Y. 2000).
64.
Gaudreault v. Municipality of Salem, Mass., 923 F.2d 203, 208 (1st Cir. 1990) (citing Laaman v, Helgemoe, 437 F. Supp. 269, 311(D.N.H. 1977)); Monmouth Cnty. Corr. Institutional Inmates v. Lanzaro, 834 F.2d 326, 347 (3d Cir. 1987); Gutierrez v. Peters, 111 F.3d 1364, 1373 (7th Cir. 1997); Sheldon v. Pezley, 49 F.3d 1312, 1316 (8th Cir. 1995); Ramos v. Lamm, 639 F.2d 559, 575 (10th Cir. 1980); Hill v. Dekalb Reg’l Youth Det. Ctr., 40 F.3d 1176, 1187 (11th Cir. 1994).
65.
Brock v. Wright, 315 F.3d 158, 162 (2d Cir. 2003) (quoting Chance v. Armstrong, 143 F.3d 698, 702 (2d Cir. 1998)). See also McGuckin v. Smith, 974 F.2d 1050, 1059-60 (9th Cir. 1992), overruled in part on other grounds by WMX Techs., Inc. v. Miller, 104 F.3d 1133, 1135 (9th Cir. 1997).
66.
W.J. Rold, “Thirty Years After Estelle v. Gamble: A Legal Retrospective,” Journal of Correctional Health Care 14 (2008): 11-20, at 16.
67.
Davis v. Carter, 452 F.3d 686, 689-90 (7th Cir. 2006); Demouchette v. Dart, 2015 U.S. Dist. LEXIS 18582, at *11 (N.D. Ill.); Idyle v. N.C. Dep’t of Corr. Med. Dep’t, 2014 U.S. Dist. LEXIS 13765, at *6 (E.D.N.C.); Meiller v. Pasco County, 2010 U.S. Dist. LEXIS 140523, at *26-27 (M.D. Fla.); Alvarado v. Westchester County, 22 F. Supp. 3d 208, 217 (S.D.N.Y. 2014); Sylvester v. City of Newark, 120 Fed. Appx. 419, 423 (3d Cir. 2005); Quatroy v. Jefferson Parish Sheriff ’s Office, 2009 U.S. Dist. LEXIS 40807, at *27-28 (E.D. L.A.); Gonzalez v. Cecil County, 221 F. Supp. 2d 611, 616 (D. Md. 2002); Butler, 2006 U.S. Dist. LEXIS 55845 at *17-18.
68.
See e.g., Iacovangelo v. Corr. Med. Care, Inc., 624 Fed. Appx. 10, 13 (2d Cir. 2015); Shaver v. Brimfield Twp., 2014 U.S. Dist. LEXIS 180571, at *41 (N.D. Ohio).
69.
United States ex rel. Walker v. Fayette County, 599 F.2d 573, 576 (3d Cir. 1979).
70.
Demouchette, 2015 U.S. Dist. LEXIS 18582 at *13.
71.
Quatroy, 2009 U.S. Dist. LEXIS 40807 at *5.
72.
Messina v. Mazzeo, 854 F. Supp. 116, 140 (E.D.N.Y. 1994).
73.
Helling, 509 U.S. at 36.
74.
N.D.Volkow, National Institute on Drug Abuse, Drugs, Brains, and Behavior: The Science of Addiction, NIH Pub. No. 14-5605 (revised July2014): at 5.
75.
D.S.Hasinet al., “DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale,”American Journal of Psychiatry170 (2013): 835-851, at 836.
76.
L.Jessellet al., “Sexual Violence in the Context of Drug Use Among Young Adult Opioid Users in New York City,”Journal of Interpersonal Violence32 (2015): 2929-2954, at 2931.
77.
R.K.Brooneret al., “Psychiatric and Substance use Comorbidity Among Treatment-Seeking Opioid Abusers,”Archives of General Psychiatry54 (1997): 71-80, at 74.
78.
B.Winklbauret al., “Treating Pregnant Women Dependent on Opioids is not the Same as Treating Pregnancy and Opioid Dependence: A Knowledge Synthesis for Better Treatment for Women and Neonates,”Addiction103 (2008): 1429-1440, at 1429-30.
79.
M.V.Ronanet al., “Hospitalizations Related to Opioid Abuse/Dependence and Associated Serious Infections from 2002 to 2012,”Health Affairs35 (2016): 832-837, at 836.
80.
Teessonet al., “Long-Term Mortality, Remission, Criminality and Psychiatric Comorbidity of Heroin Dependence: 11-year Findings from the Australian Treatment Outcome Study,”Addiction110 (2015): 986-993, at 991.
81.
M.A.Schuckit, “Treatment of Opioid Use Disorders,”N. Engl. J. Med.375 (2016): 357-268, at 357.
82.
M.Connocket al., “Methadone and Buprenorphine for the Management of Opioid Dependence: A Systematic Review and Economic Evaluation,”Health Technology Assessment11, no. 9 (2007): 1-6, at 3.
83.
B.A.Mooreet al., “Primary Care Office-Based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients,”Journal of General Internal Medicine22 (2007): 527-30.
84.
R.D.Weisset al., “Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence,”Archives of General Psychiatry68, (2011): 1238-46, at 1243.
85.
Id.
86.
See e.g., M.Farréet al., “Retention Rate and Illicit Opioid use During Methadone Maintenance Interventions: A Meta-Analysis,”Drug and Alcohol Dependence65 (2002): 283-290, at 286.
87.
See e.g., G.E.Woodyet al., “Extended vs. Short-Term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth: A Randomized Trial,”JAMA300 (2008): 2003-2011; D.A. Fiellin et al., “Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence” NEJM 355 (2006): 365-374; L.A. Marsch, “The Efficacy of Methadone Maintenance Interventions in Reducing Illicit Opiate Use, HIV Risk Behavior and Criminality: A Meta-Analysis,” Addiction 93 (1998): 515-532, at 515.
88.
M.F.Raleigh, “Buprenorphine Maintenance vs. Placebo for Opioid Dependence, American Family Physician95 (2017): 290-291, at 290.
89.
B.Arrollet al., “Efficacy and Tolerability of Tricyclic Antidepressants and SSRIs Compared With Placebo for Treatment of Depression in Primary Care: A Meta-Analysis,”Annals of Family Medicine3 (2005): 449-456, at 449.
90.
D.E.Jonaset al., “Pharmacotherapy for Adults with Alcohol use Disorders in Outpatient Settings: A Systematic Review and Meta-Analysis,”JAMA311 (2014): 1889-1900, at 1892.
91.
A.Kooyet al., “Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus,”Archives of Internal Medicine169 (2009): 615-626, at 620; J.J. Mourad et al., “Number Needed to Treat and Reduction of Outcomes with RAAS Inhibitors,” European Heart Journal 34 (2013): 1117-1118, at 1117.
92.
J.D.Leeet al., “Opioid Treatment at Release from Jail using Extended Release Naltrexone: A Pilot Proof-of-Concept Randomized Effectiveness Trial,”Addiction110 (2015): 1008-1014, at 1009.
93.
N.Kunøeet al, “Design of a Randomized Controlled Trial of Extended-Release Naltrexone Versus Daily Buprenorphine-Naloxone for Opioid Dependence in Norway (NTX-SBX)”BMC Pharmacology & Toxicology17, no. 18 (2016): 1-10.
94.
S.J.Cousinset al., “Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County,”Journal of Substance Abuse Treatment63 (2016): 66-71.
95.
Bronson, supra note 3.
96.
V.S.Westerberget al., “Community-Based Methadone Maintenance in a Large Detention Center is Associated with Decreases in Inmate Recidivism,”Journal of Substance Abuse Treatment70 (2016): 1-6, at 1.
97.
J.G.Clarkeet al., “Active and Former Injection Drug Users Report of HIV Risk Behaviors During periods of Incarceration,”Substance Abuse22 (2001): 209-216, at 213.
98.
See note 9, supra.
99.
Schuckit, supra note 81, at 357.
100.
M.E.Noonan, Bureau of Justice Statistics, Mortality in Local Jails, 2000-2014 – Statistical Tables, NCJ 250169 (December2016): 6; Pamela Lehman, “Jail Staff Trained to Use Narcan to Prevent Opioid Overdoses,” Morning Call, September 18, 2017, available at <http://www.mcall.com/news/breaking/mc-nws-narcan-jails-20170811-story.html> (last visited April 6, 2018).
101.
Noonan, supra note 100, at 6.
102.
M.E.Noonan, Bureau of Justice Statistics, Mortality in States Prisons, 2001-2014 – Statistical Tables, NCJ 250150 (December2016): 5.
Centers for Disease Control and Prevention, National Center for Health Statistics, “Underlying Cause of Death 1999-2016 on CDC WONDER Online Database,” released December, 2017, available at <http://wonder.cdc.gov/ucd-icd10.html> (last visited April 6, 2018).
105.
E.L.C.Merrallet al., “Meta-Analysis of Drug-Related Deaths Soon after Release from Prison,”Addiction105 (2010): 1545-1554, at 1549.
106.
Id.
107.
I.A.Binswangeret al., “Mortality After Prison Release: Opioid Overdose and Other Causes of Death, Risk Factors, and Time Trends from 1999-2009,”Annals of Internal Medicine159 (2013): 592-600, at 597.
108.
J.D.Richet al., “Methadone Continuation Versus Forced Withdrawal on Incarceration in a Combined US Prison and Jail: A Randomized, Open-Label Trial,”Lancet386 (2015): 350-59, at 351-52, 355-56.
109.
N.Gisevet al., “Determining the Impact of Opioid Substitution Therapy upon Mortality and Recidivism among Prisoners: A 22 Year Data Linkage Study,”Technical Report no. 330 (2014): 34.
110.
J.Marsdenet al., “Does Exposure to Opioid Substitution Treatment in Prison Reduce the Risk of Death after Release? A National Prospective Observational Study in England,”Addiction112 (2017): 1408-1418, at 1415.
111.
Clarke et al., supra note 97, at 216.
112.
Helling, 509 U.S. at 33.
113.
Plata, 563 U.S. at 509, 531-32.
114.
A.L.Beckmanet al., “New Hepatitis C Drugs Are Very Costly And Unavailable to Many State Prisoners,”Health Affairs35 (2016): 1893-1901, at 1893.; K. Stark et al., “History of Syringe Sharing in Prison, and Risk of Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus Infection among Injecting Drug Users in Berlin,” International Journal of Epidemiology 26 (1997): 1359-1366, at 1363.
N.A.Bretañaet al., “Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012,”Emerging Infections Diseases21 (2015): 765-774, at 770.
119.
S.A.Springeret al., “Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment,”Journal of Urban Health87 (2010): 592-602, at 592, 598.
120.
K.Dolanet al., “People who Inject Drugs in Prison: HIV Prevalence, Transmission and Prevention,”International Journal of Drug Policy26 (2015): 512-515, at 513.
121.
Helling, 509 U.S. at 35.
122.
Fullertonet al., “Medication-Assisted Treatment With Metha-done: Assessing the Evidence,”Psychiatric Services65 (2014): 146-157, at 153.
123.
Marsch, supra note 87, at 515.
124.
L.Gowinget al., “Substitution Treatment of Injecting Opioid Users for Prevention of HIV Infection,”Cochrane Database of Systematic Reviews2 (2008): 1-52, at 15-16.
125.
K.A.Dolanet al., “Four-Year Follow-Up of Imprisoned Male Heroin Users and Methadone Treatment: Mortality, Re-Incarceration and Hepatitis C Infection,”Addiction100 (2005): 820-28, at 824.
Dunn v. Dunn, 219 F. Supp. 3d at 1127. See also Baez, 522 F. Appx. at 821.
138.
Sain v. Wood, 512 F.3d 886, 895 (7th Cir. 2008).
139.
Inmates of Allegheny County Jail v. Pierce, 612 F.2d 754, 762 (3rd Cir. 1979)
140.
Hoptowit, 682 F.2d at 1253.
141.
Id.
142.
Harris, 941 F.2d at 1509.
143.
Hoffer 2017 U.S. Dist. LEXIS 194544, at *6.
144.
Harris, 941 F.2d at 1509.
145.
P.A.Donaher and C.Welsh, “Managing Opioid Addiction with Buprenorphine,”American Family Physician73 (2006): 1573-1578, at 1577.
146.
J.D.Richet al., “Linkage with Methadone Treatment Upon Release from Incarceration,”Journal of Addictive Diseases24 (2005): 49-59, at 56.
147.
S.Maguraet al., “Buprenorphine and Methadone Maintenance in Jail and Post-Release: A Randomized Clinical Trial,”Drug and Alcohol Dependence99 (2009): 222-230, at 227.
148.
Id. at 228.
149.
M.S.Gordonet al., “A Randomized Controlled Trial of Prison-Initiated Buprenorphine: Prison Outcomes and Community Treatment Entry,”Drug and Alcohol Dependence142 (2014): 33-40, at 38.
150.
J.T.Lin and P.Matthew, “Cancer Pain Management in Prisons: A Survey of Primary Care Practitioners and Inmates,”Journal of Pain and Symptom Management29 (2005): 466-473, at 471-472.
D.Farabeeet al., “Treatment in Criminal Justice Settings,” in N.el-Guebalyet al., eds., Textbook of Addiction Treatment: International Perspectives (Milano: Springer-Verlag Mailand, 2015): 1129-1144, at 1134-1135.
153.
Weiss et al., supra note 84, at 1244.
154.
Fiellin et al., supra note 87, at 371; R.P.Schwartzet al., “Randomized Trial of Standard Methadone Treatment Compared to Initiating Methadone without Counseling: 12-month Findings,”Addiction107 (2012): 943-952, at 950.
155.
P.D.Friedmann and R.P.Schwartz, “Just Call it ‘Treatment,’”Addiction Science & Clinical Practice7, no. 10 (2012): 1-3, at 2.
156.
Helling, 509 U.S. at 36.
157.
Rhodes v. Champan, 452 U.S. 337, 346 (1981) (quoting Trop v. Dulles, 356 U.S. 86, 101 (1958) (plurality opinion)).
158.
D. Lebowitz, supra note 13, at 297-298.
159.
Dunn, 219 F. Supp. 3d at 1128 n.37.
160.
SeeD.E.Smith, “The Evolution of Addiction Medicine as a Medical Specialty,”American Medical Association Journal of Ethics13 (2011): 900-905, at 902-903.
Combating the Opioid Abuse Epidemic: Professional and Academic Perspectives: Hearing Before the H. Comm. on Energy and Commerce, 114th Cong. (2015) (Statement of the American Medical Association).
American Psychiatric Association, “Position Statement on Treatment of Substance Use Disorders in the Criminal Justice System” (December2016).
169.
E.Malave, “Note: Prison Health Care After the Affordable Care Act: Envisioning an End to the Policy of Neglect,”New York University Law Review89 (2014): 700-738, at 730.
United States Department of Health and Human Services, Office of the Surgeon General, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, (November2016).
National Association of Drug Court Professionals, “Resolution of the Board of Directors on the Availability of Medically Asissted Treatment (M.A.T) for Addiction in Drug Courts,”available at <https://www.nadcp.org/sites/default/files/nadcp/NADCP%20Board%20Statement%20on%20MAT.pdf> (last visited April 6, 2018); See also B. Andraka-Chris-tou, “What Is ‘Treatment’ for Opioid Addiction in Problem-Solving Courts? A Study of 20 Indiana Drug and Veterans Courts,” Stanford Journal of Civil Rights and Civil Liberties 13, (2017): 189-254, at 240.
Office of Governor GinaM.Raimondo, “Raimondo Signs Ambitious Package of Bills Aimed at Preventing Overdoses and Saving Lives,” (July12, 2016), available at <http://www.ri.gov/press/view/28044> (last visited April 9, 2018).
Office of Governor GinaM.Raimondo, “Raimondo Moves to Tackle Opioid Crisis, Appoints Task Force,”August4, 2015, available at <http://www.ri.gov/press/view/25501> (last visited April 9, 2018).
D.Kaeble, L.Glaze, A.Tsoutis, and T.Minton, “Correctional Populations in the United States, 2014,”Bureau of Justice Statistics, December29, 2015, available at <https://www.bjs.gov/index.cfm?ty=pbdetail&iid=5519> (last visited April 9, 2018).
